Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease

INTRODUCTION

The hereditary peripheral neuropathies have been classified based upon clinical characteristics, mode of inheritance, electrophysiologic features, metabolic defect, and specific genetic markers. The primary hereditary neuropathies predominantly affect peripheral nerves and produce symptoms of peripheral nerve dysfunction.

Historically, the primary hereditary neuropathies were designated by eponyms that had the connotation of specific clinical features (eg, Charcot-Marie-Tooth disease or Dejerine-Sottas disease). However, phenotypic variability resulted in substantial diagnostic confusion.

The Dyck classification developed in the 1970s helped to define specific types based upon clinical and electrophysiologic features [1]. Many of the primary hereditary neuropathies were divided into motor-sensory and sensory–autonomic neuropathies.

The primary hereditary motor sensory neuropathies (HMSN) are reviewed here. The primary hereditary sensory autonomic neuropathies (HSAN), the neuropathies not included in this classification, and the disorders affecting both the central and peripheral nervous systems are discussed separately. (See "Overview of hereditary neuropathies" and "Hereditary sensory and autonomic neuropathies" and "Hereditary neuropathies associated with generalized disorders".)

BACKGROUND

Hereditary motor sensory neuropathy (HMSN), also known as Charcot-Marie-Tooth (CMT) disease, is really a spectrum of disorders caused by a specific mutation in one of several myelin genes that result in defects in myelin structure, maintenance, and formation. Each gene locus serves a specific function in maintaining myelin integrity. Gene expression can be altered by intragenic mutation but also by "gene dosage imbalance" caused by DNA duplications or deletions [2,3]. Duplication of the PMP22 gene causes CMT1A, the most common type of hereditary motor sensory neuropathy (~40 percent overall).

                         

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Aug 2014. | This topic last updated: Aug 11, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Dyck PJ. Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In: Peripheral Neuropathy, Dyck PJ, Thomas PK, Lambert EH, et al (Eds), WB Saunders, Philadelphia 1984. Vol 2.
  2. Lupski JR. Charcot-Marie-Tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity. Pediatr Res 1999; 45:159.
  3. Kamholz J, Menichella D, Jani A, et al. Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy. Brain 2000; 123 ( Pt 2):222.
  4. Klein CJ, Duan X, Shy ME. Inherited neuropathies: clinical overview and update. Muscle Nerve 2013; 48:604.
  5. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol 2013; 9:562.
  6. Mersiyanova IV, Ismailov SM, Polyakov AV, et al. Screening for mutations in the peripheral myelin genes PMP22, MPZ and Cx32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients. Hum Mutat 2000; 15:340.
  7. Roy EP 3rd, Gutmann L, Riggs JE. Longitudinal conduction studies in hereditary motor and sensory neuropathy type 1. Muscle Nerve 1989; 12:52.
  8. Rudnik-Schöneborn S, Röhrig D, Nicholson G, Zerres K. Pregnancy and delivery in Charcot-Marie-Tooth disease type 1. Neurology 1993; 43:2011.
  9. Dematteis M, Pépin JL, Jeanmart M, et al. Charcot-Marie-Tooth disease and sleep apnoea syndrome: a family study. Lancet 2001; 357:267.
  10. Dziewas R, Waldmann N, Böntert M, et al. Increased prevalence of obstructive sleep apnoea in patients with Charcot-Marie-Tooth disease: a case control study. J Neurol Neurosurg Psychiatry 2008; 79:829.
  11. Hagberg B, Lyon G. Pooled European series of hereditary peripheral neuropathies in infancy and childhood. A "correspondence work shop" report of the European Federation of Child Neurology Societies (EFCNS). Neuropediatrics 1981; 12:9.
  12. Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000; 123 ( Pt 7):1516.
  13. Videler AJ, van Dijk JP, Beelen A, et al. Motor axon loss is associated with hand dysfunction in Charcot-Marie-Tooth disease 1a. Neurology 2008; 71:1254.
  14. Bird, TD. Charcot-Marie-Tooth hereditary neuropathy overview. GeneReviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=cmt#cmt (Accessed on November 03, 2010).
  15. Gabreëls-Festen AA, Gabreëls FJ, Jennekens FG, et al. Autosomal recessive form of hereditary motor and sensory neuropathy type I. Neurology 1992; 42:1755.
  16. Hahn AF, Brown WF, Koopman WJ, Feasby TE. X-linked dominant hereditary motor and sensory neuropathy. Brain 1990; 113 ( Pt 5):1511.
  17. Bergoffen J, Trofatter J, Pericak-Vance MA, et al. Linkage localization of X-linked Charcot-Marie-Tooth disease. Am J Hum Genet 1993; 52:312.
  18. Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993; 262:2039.
  19. Shaffer LG, Kennedy GM, Spikes AS, Lupski JR. Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. Am J Med Genet 1997; 69:325.
  20. Hanemann CO, D'Urso D, Gabreëls-Festen AA, Müller HW. Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A. Brain 2000; 123 ( Pt 5):1001.
  21. Bird TD. Historical perspective of defining Charcot-Marie-Tooth type 1B. Ann N Y Acad Sci 1999; 883:6.
  22. Hayasaka K, Himoro M, Sato W, et al. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet 1993; 5:31.
  23. Wrabetz L, Feltri ML, Quattrini A, et al. P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 2000; 148:1021.
  24. Tyson J, Ellis D, Fairbrother U, et al. Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome. Brain 1997; 120 ( Pt 1):47.
  25. Maeda MH, Mitsui J, Soong BW, et al. Increased gene dosage of myelin protein zero causes Charcot-Marie-Tooth disease. Ann Neurol 2012; 71:84.
  26. Sabet A, Li J, Ghandour K, et al. Skin biopsies demonstrate MPZ splicing abnormalities in Charcot-Marie-Tooth neuropathy 1B. Neurology 2006; 67:1141.
  27. Spiryda LB. Myelin protein zero and membrane adhesion. J Neurosci Res 1998; 54:137.
  28. Matsuyama W, Nakagawa M, Takashima H, Osame M. Altered trafficking and adhesion function of MPZ mutations and phenotypes of Charcot-Marie-Tooth disease 1B. Acta Neuropathol 2002; 103:501.
  29. Lee YC, Yu CT, Lin KP, et al. MPZ mutation G123S characterization: evidence for a complex pathogenesis in CMT disease. Neurology 2008; 70:273.
  30. Street VA, Goldy JD, Golden AS, et al. Mapping of Charcot-Marie-Tooth disease type 1C to chromosome 16p identifies a novel locus for demyelinating neuropathies. Am J Hum Genet 2002; 70:244.
  31. Street VA, Bennett CL, Goldy JD, et al. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 2003; 60:22.
  32. Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998; 18:382.
  33. Kousseff BG, Hadro TA, Treiber DL, et al. Charcot-Marie-Tooth disease with sensorineural hearing loss--an autosomal dominant trait. Birth Defects Orig Artic Ser 1982; 18:223.
  34. Kovach MJ, Lin JP, Boyadjiev S, et al. A unique point mutation in the PMP22 gene is associated with Charcot-Marie-Tooth disease and deafness. Am J Hum Genet 1999; 64:1580.
  35. Jordanova A, De Jonghe P, Boerkoel CF, et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 2003; 126:590.
  36. Planté-Bordeneuve V, Guiochon-Mantel A, Lacroix C, et al. The Roussy-Lévy family: from the original description to the gene. Ann Neurol 1999; 46:770.
  37. Auer-Grumbach M, Strasser-Fuchs S, Wagner K, et al. Roussy-Lévy syndrome is a phenotypic variant of Charcot-Marie-Tooth syndrome IA associated with a duplication on chromosome 17p11.2. J Neurol Sci 1998; 154:72.
  38. Keller MP, Chance PF. Inherited peripheral neuropathy. Semin Neurol 1999; 19:353.
  39. Reilly MM. Axonal Charcot-Marie-Tooth disease: the fog is slowly lifting! Neurology 2005; 65:186.
  40. Bennett CL, Lawson VH, Brickell KL, et al. Late-onset hereditary axonal neuropathies. Neurology 2008; 71:14.
  41. Calvo J, Funalot B, Ouvrier RA, et al. Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. Arch Neurol 2009; 66:1511.
  42. Ouvrier R, Grew S. Mechanisms of disease and clinical features of mutations of the gene for mitofusin 2: an important cause of hereditary peripheral neuropathy with striking clinical variability in children and adults. Dev Med Child Neurol 2010; 52:328.
  43. Polke JM, Laurá M, Pareyson D, et al. Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology 2011; 77:168.
  44. Marrosu MG, Vaccargiu S, Marrosu G, et al. Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene. Neurology 1998; 50:1397.
  45. Senderek J, Hermanns B, Lehmann U, et al. Charcot-Marie-Tooth neuropathy type 2 and P0 point mutations: two novel amino acid substitutions (Asp61Gly; Tyr119Cys) and a possible "hotspot" on Thr124Met. Brain Pathol 2000; 10:235.
  46. Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000; 67:37.
  47. De Jonghe P, Mersivanova I, Nelis E, et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol 2001; 49:245.
  48. Yum SW, Zhang J, Mo K, et al. A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy. Ann Neurol 2009; 66:759.
  49. Fabrizi GM, Ferrarini M, Cavallaro T, et al. Two novel mutations in dynamin-2 cause axonal Charcot-Marie-Tooth disease. Neurology 2007; 69:291.
  50. Claeys KG, Züchner S, Kennerson M, et al. Phenotypic spectrum of dynamin 2 mutations in Charcot-Marie-Tooth neuropathy. Brain 2009; 132:1741.
  51. Pitceathly RD, Murphy SM, Cottenie E, et al. Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. Neurology 2012; 79:1145.
  52. Bouhouche A, Benomar A, Birouk N, et al. A locus for an axonal form of autosomal recessive Charcot-Marie-Tooth disease maps to chromosome 1q21.2-q21.3. Am J Hum Genet 1999; 65:722.
  53. Bouhouche A, Birouk N, Azzedine H, et al. Autosomal recessive axonal Charcot-Marie-Tooth disease (ARCMT2): phenotype-genotype correlations in 13 Moroccan families. Brain 2007; 130:1062.
  54. Ouvrier R, Geevasingha N, Ryan MM. Autosomal-recessive and X-linked forms of hereditary motor and sensory neuropathy in childhood. Muscle Nerve 2007; 36:131.
  55. Bienfait HM, Baas F, Koelman JH, et al. Phenotype of Charcot-Marie-Tooth disease Type 2. Neurology 2007; 68:1658.
  56. Ben Othmane K, Middleton LT, Loprest LJ, et al. Localization of a gene (CMT2A) for autosomal dominant Charcot-Marie-Tooth disease type 2 to chromosome 1p and evidence of genetic heterogeneity. Genomics 1993; 17:370.
  57. Züchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36:449.
  58. Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 2005; 65:197.
  59. Feely SM, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 2011; 76:1690.
  60. Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 2001; 105:587.
  61. Bissar-Tadmouri N, Nelis E, Züchner S, et al. Absence of KIF1B mutation in a large Turkish CMT2A family suggests involvement of a second gene. Neurology 2004; 62:1522.
  62. Elliott JL, Kwon JM, Goodfellow PJ, Yee WC. Hereditary motor and sensory neuropathy IIB: clinical and electrodiagnostic characteristics. Neurology 1997; 48:23.
  63. Verhoeven K, De Jonghe P, Coen K, et al. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 2003; 72:722.
  64. Klein CJ, Cunningham JM, Atkinson EJ, et al. The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders. Neurology 2003; 60:1151.
  65. McEntagart ME, Reid SL, Irrthum A, et al. Confirmation of a hereditary motor and sensory neuropathy IIC locus at chromosome 12q23-q24. Ann Neurol 2005; 57:293.
  66. Auer-Grumbach M, Olschewski A, Papić L, et al. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet 2010; 42:160.
  67. Chen DH, Sul Y, Weiss M, et al. CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 gene. Neurology 2010; 75:1968.
  68. Ionasescu V, Searby C, Sheffield VC, et al. Autosomal dominant Charcot-Marie-Tooth axonal neuropathy mapped on chromosome 7p (CMT2D). Hum Mol Genet 1996; 5:1373.
  69. Antonellis A, Ellsworth RE, Sambuughin N, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003; 72:1293.
  70. Fabrizi GM, Cavallaro T, Angiari C, et al. Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton. Brain 2007; 130:394.
  71. Ismailov SM, Fedotov VP, Dadali EL, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21. Eur J Hum Genet 2001; 9:646.
  72. Evgrafov OV, Mersiyanova I, Irobi J, et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 2004; 36:602.
  73. Nelis E, Berciano J, Verpoorten N, et al. Autosomal dominant axonal Charcot-Marie-Tooth disease type 2 (CMT2G) maps to chromosome 12q12-q13.3. J Med Genet 2004; 41:193.
  74. Chapon F, Latour P, Diraison P, et al. Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene. J Neurol Neurosurg Psychiatry 1999; 66:779.
  75. De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 1999; 122 ( Pt 2):281.
  76. Misu K, Yoshihara T, Shikama Y, et al. An axonal form of Charcot-Marie-Tooth disease showing distinctive features in association with mutations in the peripheral myelin protein zero gene (Thr124Met or Asp75Val). J Neurol Neurosurg Psychiatry 2000; 69:806.
  77. Hattori N, Yamamoto M, Yoshihara T, et al. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain 2003; 126:134.
  78. Birouk N, Azzedine H, Dubourg O, et al. Phenotypical features of a Moroccan family with autosomal recessive Charcot-Marie-Tooth disease associated with the S194X mutation in the GDAP1 gene. Arch Neurol 2003; 60:598.
  79. Chung KW, Kim SM, Sunwoo IN, et al. A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease. J Hum Genet 2008; 53:360.
  80. Crimella C, Tonelli A, Airoldi G, et al. The GST domain of GDAP1 is a frequent target of mutations in the dominant form of axonal Charcot Marie Tooth type 2K. J Med Genet 2010; 47:712.
  81. Tang BS, Luo W, Xia K, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24. Hum Genet 2004; 114:527.
  82. Irobi J, Van Impe K, Seeman P, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet 2004; 36:597.
  83. Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 2009; 8:654.
  84. Boerkoel CF, Takashima H, Lupski JR. The genetic convergence of Charcot-Marie-Tooth disease types 1 and 2 and the role of genetics in sporadic neuropathy. Curr Neurol Neurosci Rep 2002; 2:70.
  85. Latour P, Lévy N, Paret M, et al. Mutations in the X-linked form of Charcot-Marie-Tooth disease in the French population. Neurogenetics 1997; 1:117.
  86. Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007; 68:849.
  87. Yiu EM, Geevasinga N, Nicholson GA, et al. A retrospective review of X-linked Charcot-Marie-Tooth disease in childhood. Neurology 2011; 76:461.
  88. Al-Mateen M, Craig AK, Chance PF. The central nervous system phenotype of X-linked Charcot-Marie-Tooth disease: a transient disorder of children and young adults. J Child Neurol 2014; 29:342.
  89. Basu A, Horvath R, Esisi B, et al. Recurrent stroke-like episodes in X-linked Charcot-Marie-Tooth disease. Neurology 2011; 77:1205.
  90. Paulson HL, Garbern JY, Hoban TF, et al. Transient central nervous system white matter abnormality in X-linked Charcot-Marie-Tooth disease. Ann Neurol 2002; 52:429.
  91. Taylor RA, Simon EM, Marks HG, Scherer SS. The CNS phenotype of X-linked Charcot-Marie-Tooth disease: more than a peripheral problem. Neurology 2003; 61:1475.
  92. Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology 1993; 43:2558.
  93. Ionasescu VV, Trofatter J, Haines JL, et al. Heterogeneity in X-linked recessive Charcot-Marie-Tooth neuropathy. Am J Hum Genet 1991; 48:1075.
  94. Ionasescu VV, Trofatter J, Haines JL, et al. X-linked recessive Charcot-Marie-Tooth neuropathy: clinical and genetic study. Muscle Nerve 1992; 15:368.
  95. Huttner IG, Kennerson ML, Reddel SW, et al. Proof of genetic heterogeneity in X-linked Charcot-Marie-Tooth disease. Neurology 2006; 67:2016.
  96. Cowchock FS, Duckett SW, Streletz LJ, et al. X-linked motor-sensory neuropathy type-II with deafness and mental retardation: a new disorder. Am J Med Genet 1985; 20:307.
  97. Priest JM, Fischbeck KH, Nouri N, Keats BJ. A locus for axonal motor-sensory neuropathy with deafness and mental retardation maps to Xq24-q26. Genomics 1995; 29:409.
  98. Kim HJ, Hong SH, Ki CS, et al. A novel locus for X-linked recessive CMT with deafness and optic neuropathy maps to Xq21.32-q24. Neurology 2005; 64:1964.
  99. Salisachs P. Wide spectrum of motor conduction velocity in Charcot-Marie-Tooth disease. An anatomico-physiological interpretation. J Neurol Sci 1974; 23:25.
  100. Davis CJ, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J Genet Hum 1978; 26:311.
  101. Rossi A, Paradiso C, Cioni R, et al. Charcot-Marie-Tooth disease: study of a large kinship with an intermediate form. J Neurol 1985; 232:91.
  102. Verhoeven K, Villanova M, Rossi A, et al. Localization of the gene for the intermediate form of Charcot-Marie-Tooth to chromosome 10q24.1-q25.1. Am J Hum Genet 2001; 69:889.
  103. Kennerson ML, Zhu D, Gardner RJ, et al. Dominant intermediate Charcot-Marie-Tooth neuropathy maps to chromosome 19p12-p13.2. Am J Hum Genet 2001; 69:883.
  104. Züchner S, Noureddine M, Kennerson M, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet 2005; 37:289.
  105. Jordanova A, Thomas FP, Guergueltcheva V, et al. Dominant intermediate Charcot-Marie-Tooth type C maps to chromosome 1p34-p35. Am J Hum Genet 2003; 73:1423.
  106. Jordanova A, Irobi J, Thomas FP, et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet 2006; 38:197.
  107. Mastaglia FL, Nowak KJ, Stell R, et al. Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry 1999; 67:174.
  108. Banchs I, Casasnovas C, Montero J, et al. Charcot-Marie-Tooth disease with intermediate conduction velocities caused by a novel mutation in the MPZ gene. Muscle Nerve 2010; 42:184.
  109. Ouvrier RA, McLeod JG, Conchin TE. The hypertrophic forms of hereditary motor and sensory neuropathy. A study of hypertrophic Charcot-Marie-Tooth disease (HMSN type I) and Dejerine-Sottas disease (HMSN type III) in childhood. Brain 1987; 110 ( Pt 1):121.
  110. Parman Y, Battaloglu E, Baris I, et al. Clinicopathological and genetic study of early-onset demyelinating neuropathy. Brain 2004; 127:2540.
  111. Parman Y, Planté-Bordeneuve V, Guiochon-Mantel A, et al. Recessive inheritance of a new point mutation of the PMP22 gene in Dejerine-Sottas disease. Ann Neurol 1999; 45:518.
  112. Ikegami T, Ikeda H, Aoyama M, et al. Novel mutations of the peripheral myelin protein 22 gene in two pedigrees with Dejerine-Sottas disease. Hum Genet 1998; 102:294.
  113. Timmerman V, De Jonghe P, Ceuterick C, et al. Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology 1999; 52:1827.
  114. Boerkoel CF, Takashima H, Bacino CA, et al. EGR2 mutation R359W causes a spectrum of Dejerine-Sottas neuropathy. Neurogenetics 2001; 3:153.
  115. Boerkoel CF, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet 2001; 68:325.
  116. Charnas L, Trapp B, Griffin J. Congenital absence of peripheral myelin: abnormal Schwann cell development causes lethal arthrogryposis multiplex congenita. Neurology 1988; 38:966.
  117. Ghamdi M, Armstrong DL, Miller G. Congenital hypomyelinating neuropathy: a reversible case. Pediatr Neurol 1997; 16:71.
  118. Levy BK, Fenton GA, Loaiza S, Hayat GR. Unexpected recovery in a newborn with severe hypomyelinating neuropathy. Pediatr Neurol 1997; 16:245.
  119. Phillips JP, Warner LE, Lupski JR, Garg BP. Congenital hypomyelinating neuropathy: two patients with long-term follow-up. Pediatr Neurol 1999; 20:226.
  120. Mandich P, Mancardi GL, Varese A, et al. Congenital hypomyelination due to myelin protein zero Q215X mutation. Ann Neurol 1999; 45:676.
  121. Kochanski A, Drac H, Kabzińska D, et al. A novel MPZ gene mutation in congenital neuropathy with hypomyelination. Neurology 2004; 62:2122.
  122. Bolino A, Lonie LJ, Zimmer M, et al. Denaturing high-performance liquid chromatography of the myotubularin-related 2 gene (MTMR2) in unrelated patients with Charcot-Marie-Tooth disease suggests a low frequency of mutation in inherited neuropathy. Neurogenetics 2001; 3:107.
  123. Bird, TD. Charcot-Marie-Tooth neuropathy type 4. Gene Reviews. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=cmt4 (Accessed on November 03, 2010).
  124. Ben Othmane K, Hentati F, Lennon F, et al. Linkage of a locus (CMT4A) for autosomal recessive Charcot-Marie-Tooth disease to chromosome 8q. Hum Mol Genet 1993; 2:1625.
  125. Baxter RV, Ben Othmane K, Rochelle JM, et al. Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet 2002; 30:21.
  126. Cuesta A, Pedrola L, Sevilla T, et al. The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet 2002; 30:22.
  127. Pedrola L, Espert A, Wu X, et al. GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. Hum Mol Genet 2005; 14:1087.
  128. Bolino A, Brancolini V, Bono F, et al. Localization of a gene responsible for autosomal recessive demyelinating neuropathy with focally folded myelin sheaths to chromosome 11q23 by homozygosity mapping and haplotype sharing. Hum Mol Genet 1996; 5:1051.
  129. Bolino A, Levy ER, Muglia M, et al. Genetic refinement and physical mapping of the CMT4B gene on chromosome 11q22. Genomics 2000; 63:271.
  130. Quattrone A, Gambardella A, Bono F, et al. Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths: clinical, electrophysiologic, and genetic aspects of a large family. Neurology 1996; 46:1318.
  131. Bolino A, Muglia M, Conforti FL, et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 2000; 25:17.
  132. Othmane KB, Johnson E, Menold M, et al. Identification of a new locus for autosomal recessive Charcot-Marie-Tooth disease with focally folded myelin on chromosome 11p15. Genomics 1999; 62:344.
  133. Hirano R, Takashima H, Umehara F, et al. SET binding factor 2 (SBF2) mutation causes CMT4B with juvenile onset glaucoma. Neurology 2004; 63:577.
  134. Senderek J, Bergmann C, Weber S, et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 2003; 12:349.
  135. Azzedine H, Bolino A, Taïeb T, et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet 2003; 72:1141.
  136. Kiwaki T, Umehara F, Takashima H, et al. Hereditary motor and sensory neuropathy with myelin folding and juvenile onset glaucoma. Neurology 2000; 55:392.
  137. Gambardella A, Bolino A, Muglia M, et al. Genetic heterogeneity in autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths (CMT4B). Neurology 1998; 50:799.
  138. Conforti FL, Muglia M, Mazzei R, et al. A new SBF2 mutation in a family with recessive demyelinating Charcot-Marie-Tooth (CMT4B2). Neurology 2004; 63:1327.
  139. Nakhro K, Park JM, Hong YB, et al. SET binding factor 1 (SBF1) mutation causes Charcot-Marie-Tooth disease type 4B3. Neurology 2013; 81:165.
  140. LeGuern E, Guilbot A, Kessali M, et al. Homozygosity mapping of an autosomal recessive form of demyelinating Charcot-Marie-Tooth disease to chromosome 5q23-q33. Hum Mol Genet 1996; 5:1685.
  141. Gabreëls-Festen A, van Beersum S, Eshuis L, et al. Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33. J Neurol Neurosurg Psychiatry 1999; 66:569.
  142. Guilbot A, Ravisé N, Bouhouche A, et al. Genetic, cytogenetic and physical refinement of the autosomal recessive CMT linked to 5q31-q33: exclusion of candidate genes including EGR1. Eur J Hum Genet 1999; 7:849.
  143. Senderek J, Bergmann C, Stendel C, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet 2003; 73:1106.
  144. Azzedine H, Ravisé N, Verny C, et al. Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. Neurology 2006; 67:602.
  145. Kalaydjieva L, Hallmayer J, Chandler D, et al. Gene mapping in Gypsies identifies a novel demyelinating neuropathy on chromosome 8q24. Nat Genet 1996; 14:214.
  146. Kalaydjieva L, Gresham D, Gooding R, et al. N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet 2000; 67:47.
  147. Guilbot A, Williams A, Ravisé N, et al. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet 2001; 10:415.
  148. De Sandre-Giovannoli A, Delague V, Hamadouche T, et al. Homozygosity mapping of autosomal recessive demyelinating Charcot-Marie-Tooth neuropathy (CMT4H) to a novel locus on chromosome 12p11.21-q13.11. J Med Genet 2005; 42:260.
  149. Stendel C, Roos A, Deconinck T, et al. Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4. Am J Hum Genet 2007; 81:158.
  150. Fabrizi GM, Taioli F, Cavallaro T, et al. Further evidence that mutations in FGD4/frabin cause Charcot-Marie-Tooth disease type 4H. Neurology 2009; 72:1160.
  151. Chow CY, Zhang Y, Dowling JJ, et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 2007; 448:68.
  152. Zhang X, Chow CY, Sahenk Z, et al. Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. Brain 2008; 131:1990.
  153. Echaniz-Laguna A, Ghezzi D, Chassagne M, et al. SURF1 deficiency causes demyelinating Charcot-Marie-Tooth disease. Neurology 2013; 81:1523.
  154. Amato AA, Reilly MM. The death panel for Charcot-Marie-Tooth panels. Ann Neurol 2011; 69:1.
  155. Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69:22.
  156. Sereda MW, Meyer zu Hörste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003; 9:1533.
  157. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10:396.
  158. Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009; 8:537.
  159. Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009; 8:1103.
  160. Pareyson D, Solari A. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective? Lancet Neurol 2009; 8:1075.
  161. Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005; 65:681.
  162. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003; 60:337.
  163. Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci 2006; 242:47.
  164. Guay J. First, do no harm: balancing the risks and benefits of regional anesthesia in patients with underlying neurological disease. Can J Anaesth 2008; 55:489.
  165. Greenwood JJ, Scott WE. Charcot-Marie-Tooth disease: peripartum management of two contrasting clinical cases. Int J Obstet Anesth 2007; 16:149.
  166. Dhir S, Balasubramanian S, Ross D. Ultrasound-guided peripheral regional blockade in patients with Charcot-Marie-Tooth disease: a review of three cases. Can J Anaesth 2008; 55:515.
  167. Brock M, Guinn C, Jones M. Anesthetic management of an obstetric patient with Charcot-Marie-Tooth disease: a case study. AANA J 2009; 77:335.